Promising whole‐cell vaccines against cryptococcosis

Le résumé fourni par la source

Abstract Cryptococcosis is a mycosis caused by Cryptococcus neoformans and C. gattii species complexes. Although this infection is potentially lethal, no prophylactic vaccine is yet commercially available, and the immune memory that enables prevention is still under investigation. These pathogens have a capsule layer for immune evasion and a sophisticated mechanism to advance the infection, and it is expected that these characteristics will make it difficult to develop prophylactic vaccines and to decipher the protective immunity. The current vaccine studies are focused on subunit, mRNA, DNA, and viral vector vaccines, with whole‐cell vaccines also proving successful against cryptococcal infections. Cryptococcal whole‐cell vaccines have been composed of highly immunostimulating strains with low‐pathogenicity that are modified by genetic recombination technology. Examples include the whole‐cell vaccines H99γ, sgl1∆, fbp1∆, znf2oe, cda1/2/3∆, cap59∆, and cap60∆. Some of these whole‐cell vaccines were found to be highly effective in prolonging life and suppressing the fungal burden after an infection challenge in mice, and to be cross‐reactive to C. neoformans, C. gattii, and other fungal pathogens. Furthermore, for some vaccines, the protective effect can be retained even in an immunocompromised host depleted of CD4+ T cells. These findings have provided new insights into protective immunity that should aid in vaccine development. In this review, we highlight the upsides and downsides of whole‐cell vaccines against cryptococcosis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.